1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Alice Mims: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Azacitidine, Biopsy, Enasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Alice Mims | 125 | 2022-09-13 | 2026-06-23 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia mitoxantrone hydrochloride, etoposide, cytarabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alice Mims | 23 | 2015-05-18 | 2023-06-15 |
Leukemia, Myeloid, Acute (2) · Congenital Abnormalities (1)
Azacitidine (1) · Biopsy (1) · Cytarabine (1) · Etoposide (1) · Mitoxantrone (1) · enasidenib (1) · ivosidenib (1) · selinexor (1) · venetoclax (1)
United States (2)
Alice S Mims, MD (1)
R01CA262496 (1)